INSM
Insmed Incorporated·Healthcare
154.81
2.995%(−4.78)
Close PriceLast Updated: — ET
52W L: $63.8152W H: $212.75
INSM NEWS
247wallst.com
19h ago
Here Are Friday’s Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
Pre-Market Stock Futures: The futures are trading mixed as we approach the end of one of the most volatile and wild trading weeks in recent memory. After starting the day lower on Thursday as mixed reports on the success of the ships passing through the Strait of Hormuz rolled in, stocks gained momentum as the... Here Are Friday's Top Wall Street Analyst Research Calls: Autodesk, Delek US Holdings, Insmed, Nike, Nutanix, ServiceNow, Shake Shack, Southern Copper, Veeva Systems, and More
zacks.com
2d ago
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.
reuters.com
3d ago
Insmed discontinues development of skin condition drug after mid-stage study miss
Insmed said on Tuesday it would discontinue the development of its treatment for a chronic, inflammatory skin condition, after the drug failed a mid-stage trial.
prnewswire.com
3d ago
Insmed Provides Clinical Update on Phase 2b CEDAR Study
—Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.
defenseworld.net
4d ago
Park Capital Management LLC WI Invests $1.04 Million in Insmed, Inc. $INSM
Park Capital Management LLC WI acquired a new position in Insmed, Inc. (NASDAQ: INSM) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,989 shares of the biopharmaceutical company's stock, valued at approximately $1,042,000. Insmed comprises approximately
defenseworld.net
Apr 3
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares of Stock
Insmed, Inc. (NASDAQ: INSM - Get Free Report) insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the transaction, the insider owned 51,871 shares in the company, valued
